Log in

NASDAQ:INCYIncyte Stock Price, Forecast & News

$94.87
-0.69 (-0.72 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$94.28
Now: $94.87
$96.42
50-Day Range
$92.98
MA: $101.93
$109.69
52-Week Range
$62.48
Now: $94.87
$110.36
Volume891,184 shs
Average Volume1.74 million shs
Market Capitalization$20.75 billion
P/E RatioN/A
Dividend YieldN/A
Beta1
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Read More
Incyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$2.45 per share
Book Value$12.06 per share

Profitability

Net Income$446.91 million

Miscellaneous

Employees1,456
Market Cap$20.75 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$94.87
-0.69 (-0.72 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Incyte (NASDAQ:INCY) Frequently Asked Questions

How has Incyte's stock price been impacted by COVID-19 (Coronavirus)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INCY shares have increased by 31.9% and is now trading at $94.87.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Incyte?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Incyte
.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Incyte
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) announced its earnings results on Tuesday, August, 4th. The biopharmaceutical company reported $1.04 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.68 by $0.36. The biopharmaceutical company had revenue of $688 million for the quarter, compared to analysts' expectations of $617.55 million. Incyte had a negative net margin of 8.00% and a negative return on equity of 8.06%. Incyte's revenue for the quarter was up 29.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share.
View Incyte's earnings history
.

What price target have analysts set for INCY?

23 Wall Street analysts have issued twelve-month price objectives for Incyte's stock. Their forecasts range from $83.00 to $124.00. On average, they anticipate Incyte's stock price to reach $102.30 in the next year. This suggests a possible upside of 7.8% from the stock's current price.
View analysts' price targets for Incyte
.

Has Incyte been receiving favorable news coverage?

Press coverage about INCY stock has been trending neutral on Saturday, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Incyte earned a coverage optimism score of 0.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Incyte
.

Are investors shorting Incyte?

Incyte saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 4,530,000 shares, an increase of 14.7% from the December 31st total of 3,950,000 shares. Based on an average daily trading volume, of 1,410,000 shares, the days-to-cover ratio is currently 3.2 days. Approximately 2.1% of the company's stock are short sold.
View Incyte's Short Interest
.

Who are some of Incyte's key competitors?

What other stocks do shareholders of Incyte own?

Who are Incyte's key executives?

Incyte's management team includes the following people:
  • Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.48%), Bellevue Group AG (1.51%), First Trust Advisors LP (0.89%), California Public Employees Retirement System (0.71%), Bank of New York Mellon Corp (0.65%) and Sumitomo Mitsui Trust Holdings Inc. (0.42%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte
.

Which institutional investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, State of Tennessee Treasury Department, UBS Group AG, Bank of Nova Scotia, Country Trust Bank, Sector Gamma AS, Sumitomo Mitsui Trust Holdings Inc., and Russell Investments Group Ltd.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon, and Yao Wenqing.
View insider buying and selling activity for Incyte
.

Which institutional investors are buying Incyte stock?

INCY stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, First Trust Advisors LP, TD Asset Management Inc., NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., FMR LLC, Epoch Investment Partners Inc., and Vanguard Group Inc.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Jean Jacques Bienaime.
View insider buying and selling activity for Incyte
.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $94.87.

How big of a company is Incyte?

Incyte has a market capitalization of $20.75 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.